Joseph A. Kozlowski;Stuart B. Rosenblum;Douglas W. Hobbs;Qingbei Zeng;Neng-Yang Shih;Brian F. McGuinness
发明人:
Qingbei Zeng,Stuart B. Rosenblum,Joseph A. Kozlowski,Neng-Yang Shih,Brian F. McGuinness,Douglas W. Hobbs
申请号：
US12519970
公开号：
US20120157466A1
申请日:
2007.12.20
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5:or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
